Baird analyst David Rescott raised the firm’s price target on Haemonetics (HAE) to $82 from $65 and keeps an Outperform rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics Reports Improved Profitability Amid Revenue Decline
- Haemonetics: Strong Financial Performance and Strategic Adjustments Drive Buy Rating
- Haemonetics price target raised to $88 from $85 at BTIG
- Haemonetics rises 26.1%
- Haemonetics narrows FY26 adjusted EPS view to $4.80-$5.00 from $4.70-$5.00